ValuEngine upgraded shares of TrovaGene (NASDAQ:TROV) from a strong sell rating to a sell rating in a research note published on Friday morning.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group cut shares of TrovaGene from a buy rating to a hold rating in a research note on Friday, November 10th. HC Wainwright assumed coverage on shares of TrovaGene in a research note on Thursday, December 21st. They set a buy rating and a $1.00 target price on the stock. Finally, cut shares of TrovaGene from a buy rating to a hold rating in a research note on Wednesday, November 15th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of Hold and an average target price of $3.70.

TrovaGene (TROV) opened at $0.30 on Friday. TrovaGene has a one year low of $0.23 and a one year high of $2.25. The firm has a market cap of $15.68, a P/E ratio of -0.30 and a beta of 0.26.

TrovaGene (NASDAQ:TROV) last issued its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative net margin of 7,960.05% and a negative return on equity of 259.94%. The firm had revenue of $0.12 million for the quarter. equities analysts expect that TrovaGene will post -0.78 earnings per share for the current year.

An institutional investor recently raised its position in TrovaGene stock. Susquehanna International Group LLP boosted its position in shares of TrovaGene Inc (NASDAQ:TROV) by 2,781.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 138,031 shares of the medical research company’s stock after acquiring an additional 133,240 shares during the period. Susquehanna International Group LLP owned 0.37% of TrovaGene worth $174,000 at the end of the most recent quarter. 9.86% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at

TrovaGene Company Profile

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.